All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Important announcement
British Columbia and Ontario add belumosudil, a ROCK1/2 inhibitor, to their provincial formularies for the treatment of adult and pediatric patients aged ≥12 years with chronic #GvHD after ≥2 lines of therapy.
Read more: https://bit.ly/4rvC1cc
More drug updates
VIEW ALL
MaaT013 marketing authorization application
On June 2, 2025, a marketing authorization application was submitted to the @EMA_News for MaaT013, a pooled fecal microbiota product, for the treatment of gastrointestinal acute #GvHD. This follows positive data from the Pivotal ARES study. Read more: https://businesswire.com/news/home/20250602568637/en/MaaT-Pharma-Advances-Toward-Commercialization-And-Submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-EMA-for-Xervyteg-MaaT013-in-Acute-Graft-versus-Host-Disease
Important announcement
On March 11, 2025, the EMA Pediatric Committee provided a positive opinion and cleared the pediatric investigation plan to assess MaaT013 in patients from 6 years old to <18 years old with aGvHD. The study is planned to start in 2026. Read more: https://businesswire.com/news/home/20250311353696/en/MaaT-Pharma-Receives-Positive-Opinion-from-EMA-Pediatric-Committee-on-the-Pediatric-Investigation-Plan-for-MaaT013